Could a pill shrink bladder tumors before surgery?
NCT ID NCT03914794
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested pemigatinib, a daily pill that blocks certain growth signals, in 30 people with recurrent low- or intermediate-risk non-muscle invasive bladder cancer. Participants took the drug for 4-6 weeks before their standard surgery to remove bladder tumors. The main goal was to see if the drug could make tumors disappear completely before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pemigatinib (a drug that blocks certain growth signals in cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with recurrent low- or intermediate-risk bladder cancer, potentially reducing the need for repeated surgeries.
What could go wrong
This is a small, early-phase trial with only 30 participants. The drug may not work for everyone, and side effects are possible. Results may not apply to all bladder cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Associated Medical Professionals Urology
Syracuse, New York, 13210, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
-
Keystone Urology
Lancaster, Pennsylvania, 17604, United States
-
Midlantic Urology
Bala-Cynwyd, Pennsylvania, 19004, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States